Cover Image
市場調查報告書

出血:開發中產品分析

Hemorrhage - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 245979
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
出血:開發中產品分析 Hemorrhage - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 44 Pages
簡介

所謂出血是由於血液過度流出造成的疾病,主要原因有肝臟疾病和出血障礙,高血壓,傷害,動脈瘤等。主要的症狀有噁心和嘔吐,吞嚥障礙,協調能力喪失,意識不明,沉重的頭痛,刺痛等。

本報告提供全球各國治療出血所用的開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發 (R&D) 的發展情形),最新的產業趨勢等資訊。

簡介

  • 分析範圍

出血概要

治療藥的開發

  • 出血開發中產品:概要
  • 出血開發中產品:比較分析

各企業開發中的出血治療藥

大學/研究機關研究中的出血治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

出血治療藥:開發中的產品一覽(各企業)

出血治療藥:研究中的產品一覽(大學/研究機關)

出血開發治療藥的企業

  • Cellphire, Inc.
  • Digna Biotech, S.L.
  • Haemostatix Limited
  • QRxPharma Limited
  • Serendex Pharmaceuticals A/S
  • Thrombotargets Europe SL

出血:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • DB-055
  • eptacog alfa (activated)
  • PeproStat
  • Protein for Hematological Disorders, Dermatology, Shock and Injury
  • Q-8008
  • Small Molecule for Postpartum Hemorrhage
  • Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage
  • Thrombosomes
  • TT-111
  • TT-112
  • V-0801

出血治療藥:開發中產品的最新趨勢

出血治療藥:開發暫停的產品

出血相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7129IDB

Summary

Global Markets Direct's, 'Hemorrhage - Pipeline Review, H2 2015', provides an overview of the Hemorrhage's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hemorrhage
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hemorrhage and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hemorrhage
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemorrhage Overview
  • Therapeutics Development
    • Pipeline Products for Hemorrhage - Overview
    • Pipeline Products for Hemorrhage - Comparative Analysis
  • Hemorrhage - Therapeutics under Development by Companies
  • Hemorrhage - Therapeutics under Investigation by Universities/Institutes
  • Hemorrhage - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hemorrhage - Products under Development by Companies
  • Hemorrhage - Products under Investigation by Universities/Institutes
  • Hemorrhage - Companies Involved in Therapeutics Development
    • Cellphire, Inc.
    • Digna Biotech, S.L.
    • Haemostatix Limited
    • QRxPharma Limited
    • Serendex Pharmaceuticals A/S
    • Thrombotargets Europe SL
  • Hemorrhage - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DB-055 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eptacog alfa (activated) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PeproStat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Q-8008 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Postpartum Hemorrhage - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Thrombosomes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-0801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hemorrhage - Recent Pipeline Updates
  • Hemorrhage - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemorrhage, H2 2015
  • Number of Products under Development for Hemorrhage - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Hemorrhage - Pipeline by Cellphire, Inc., H2 2015
  • Hemorrhage - Pipeline by Digna Biotech, S.L., H2 2015
  • Hemorrhage - Pipeline by Haemostatix Limited, H2 2015
  • Hemorrhage - Pipeline by QRxPharma Limited, H2 2015
  • Hemorrhage - Pipeline by Serendex Pharmaceuticals A/S, H2 2015
  • Hemorrhage - Pipeline by Thrombotargets Europe SL, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Hemorrhage Therapeutics - Recent Pipeline Updates, H2 2015
  • Hemorrhage - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Hemorrhage, H2 2015
  • Number of Products under Development for Hemorrhage - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top